TNFα/Miz1正反馈环路抑制肝细胞线粒体自噬并推动非酒精性脂肪性肝炎进展
研究通过RNA测序和液相色谱-质谱分析人NASH与正常肝组织,发现肝细胞胞质蛋白Miz1在NASH中减少;Miz1结合PRDX6并阻止其与线粒体Parkin在Cys431位点相互作用,从而抑制Parkin介导的线粒体自噬;NASH中Miz1缺失导致线粒体自噬受抑、功能异常线粒体增多及巨噬细胞TNFα产生增加,TNFα又通过E3泛素化进一步降低肝细胞Miz1,形成正反馈环路。
要点
- 人NASH肝细胞中Miz1减少,Miz1通过结合PRDX6阻断其与Parkin在Cys431相互作用而抑制线粒体自噬。
- 肝细胞Miz1缺失导致PRDX6介导的线粒体自噬抑制、功能异常线粒体积累和巨噬细胞TNFα产生增加。
- TNFα通过E3泛素化进一步降低肝细胞Miz1,形成正反馈环路;阻断该环路可能是抑制NASH进展的策略。
核心结论
- 研究鉴定肝细胞Miz1通过参与线粒体自噬抑制NASH进展,并揭示TNFα产生诱导胞质Miz1降解、抑制线粒体自噬、进而增加巨噬细胞TNFα产生的正反馈环路。
- 作者认为阻断该正反馈环路可能是抑制NASH进展的策略。
研究设计与样本
- 分析人NASH与正常肝组织的RNA测序和液相色谱-质谱数据。
- 建立西方饮食加果糖诱导的NASH模型,使用肝细胞特异性Miz1敲除小鼠和腺相关病毒8型过表达小鼠。
- 使用人NASH肝类器官确认机制,并用免疫沉淀和质谱检测可与Miz1相互作用的蛋白。
主要发现
- 人NASH肝细胞中Miz1减少。
- Miz1结合过氧化物还原酶6(PRDX6),将其滞留于胞质,阻断PRDX6与线粒体Parkin在Cys431的相互作用,抑制Parkin介导的线粒体自噬。
- NASH肝脏中肝细胞Miz1缺失导致PRDX6介导的线粒体自噬抑制、肝细胞功能异常线粒体增多及肝脏巨噬细胞产生包括TNFα在内的促炎细胞因子。
- TNFα产生增加通过E3泛素化进一步降低肝细胞Miz1,形成TNFα介导肝细胞Miz1降解的正反馈环路。
临床怎么用
- 作者认为阻断TNFα介导肝细胞Miz1降解的正反馈环路可能是抑制NASH进展的策略。
- 作者认为人NASH肝类器官培养是探索NASH发展治疗策略的有用平台。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is a chronic inflammatory disease that can further progress to cirrhosis and hepatocellular carcinoma. However, the key molecular mechanisms behind this process have not been clarified. METHODS: We analyzed human NASH and normal liver tissue samples by RNA-sequencing and liquid chromatography-mass spectrometry, identifying hepatocyte cytosolic protein Myc-interacting zinc-finger protein 1 (Miz1) as a potential target in NASH progression. We established a Western diet+fructose-induced NASH model in hepatocyte-specific Miz1 knockout and adeno-associated virus type 8-overexpressing mice. Human NASH liver organoids were used to confirm the mechanism, and immunoprecipitation and mass spectrometry were used to detect proteins that could interact with Miz1. RESULTS: We demonstrate that Miz1 is reduced in hepatocytes in human NASH. Miz1 is shown to bind to peroxiredoxin 6 (PRDX6), retaining it in the cytosol, blocking its interaction with mitochondrial Parkin at Cys431, and inhibiting Parkin-mediated mitophagy. In NASH livers, loss of hepatocyte Miz1 results in PRDX6-mediated inhibition of mitophagy, increased dysfunctional mitochondria in hepatocytes, and production of proinflammatory cytokines, including TNFα, by hepatic macrophages. Crucially, the increased production of TNFα results in a further reduction in hepatocyte Miz1 by E3-ubiquitination. This produces a positive feedback loop of TNFα-mediated hepatocyte Miz1 degradation, resulting in PRDX6-mediated inhibition of hepatocyte mitophagy, with the accumulation of dysfunctional mitochondria in hepatocytes and increased macrophage TNFα production. CONCLUSIONS: Our study identified hepatocyte Miz1 as a suppressor of NASH progression via its role in mitophagy; we also identified a positive feedback loop by which TNFα production induces degradation of cytosolic Miz1, which inhibits mitophagy and thus leads to increased macrophage TNFα production. Interruption of this positive feedback loop could be a strategy to inhibit the progression of NASH. IMPACT AND IMPLICATIONS: Non-alcoholic steatohepatitis (NASH) is a chronic inflammatory disease that can further develop into cirrhosis and hepatocellular carcinoma. However, the key molecular mechanism of this process has not been fully clarified. Herein, we identified a positive feedback loop of macrophage TNFα-mediated hepatocyte Miz1 degradation, resulting in PRDX6-mediated inhibition of hepatocyte mitophagy, aggravation of mitochondrial damage and increased macrophage TNFα production. Our findings not only provide mechanistic insight into NASH progression but also provide potential therapeutic targets for patients with NASH. Our human NASH liver organoid culture is therefore a useful platform for exploring treatment strategies for NASH development.
引用
- Jin K, Shi Y, Zhang H, et al. A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis. J Hepatol. 2023. PMID: 37040844. doi:10.1016/j.jhep.2023.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。